- Home
- TCI vs MGNX Comparison
TCI vs MGNX Comparison
Compare TCI & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCI
- MGNX
- Stock Information
- Founded
- TCI 1983
- MGNX 2000
- Country
- TCI United States
- MGNX United States
- Employees
- TCI N/A
- MGNX N/A
- Industry
- TCI Real Estate
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- TCI Finance
- MGNX Health Care
- Exchange
- TCI Nasdaq
- MGNX Nasdaq
- Market Cap
- TCI 240.5M
- MGNX 257.3M
- IPO Year
- TCI N/A
- MGNX 2013
- Fundamental
- Price
- TCI $27.45
- MGNX $3.57
- Analyst Decision
- TCI
- MGNX Buy
- Analyst Count
- TCI 0
- MGNX 11
- Target Price
- TCI N/A
- MGNX $8.57
- AVG Volume (30 Days)
- TCI 2.2K
- MGNX 751.3K
- Earning Date
- TCI 11-07-2024
- MGNX 11-05-2024
- Dividend Yield
- TCI N/A
- MGNX N/A
- EPS Growth
- TCI N/A
- MGNX N/A
- EPS
- TCI 0.37
- MGNX N/A
- Revenue
- TCI $49,821,000.00
- MGNX $141,329,000.00
- Revenue This Year
- TCI N/A
- MGNX $119.63
- Revenue Next Year
- TCI N/A
- MGNX N/A
- P/E Ratio
- TCI $74.27
- MGNX N/A
- Revenue Growth
- TCI 4.46
- MGNX 16.68
- 52 Week Low
- TCI $26.29
- MGNX $2.95
- 52 Week High
- TCI $43.40
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- TCI 45.32
- MGNX 44.98
- Support Level
- TCI $26.29
- MGNX $3.63
- Resistance Level
- TCI $28.09
- MGNX $5.10
- Average True Range (ATR)
- TCI 0.53
- MGNX 0.38
- MACD
- TCI 0.01
- MGNX -0.03
- Stochastic Oscillator
- TCI 53.46
- MGNX 22.18
About TCI Transcontinental Realty Investors Inc.
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).